ArticleAnnals of hematology2022

Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.

Yosuke Masamoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.